UNSPSC 51124001: Benrixate

This classification denotes an antiarrhythmic agent with the molecular formula C19H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 58NL35I27K, chemically known as 4-benzyl-1-piperidinecarboxylic acid, 2-(diethylamino)ethyl ester but more generally known as benrixate, which bears US NIH Compound Identifier 184848. European Medicines Agency schedules Benrixate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05729MIG.

UNSPSC 51124001 Benrixate, a Commodity code, describes pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and institutional healthcare operations. State and local buyers under this code acquire specific advanced life support medications, generic pharmaceuticals, and over-the-counter products through competitive sealed bids, requests for proposal, and cooperative purchasing arrangements. Recent solicitations show municipalities and state health agencies sourcing individual medication line items in defined quantities, manufacturers supplying products through authorized wholesale distributors under multi-year framework agreements, and state pharmacy benefit programs implementing direct-to-manufacturer procurement models to manage costs and improve fulfillment. Issuing bodies include city fire-rescue departments (Tampa Fire Rescue via the City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes Oregon participants).

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials—with responses due April 8, 2026 and an estimated contract value of $40,000.00; the contract carries a one-year base term with two optional one-year renewals, a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount capped at $10,000, and requires vendors to maintain nine-month expiration windows and deliver within ten calendar days. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement development ahead of a formal RFP. MMCAP posted an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with contract effectiveness July 1, 2026 and a two-year base term. All three solicitations require FDA compliance, Safety Data Sheets, current Good Manufacturing Practices certification, and expiration-date assurances ranging from nine months to one year from acceptance or manufacture.